Background—Chagas disease remains a significant public health issue and a major cause
of morbidity and mortality in Latin America. Despite nearly 1 century of research, the …

A critical review of the development of specific chemotherapeutic approaches for the
management of American Trypanosomiasis or Chagas disease is presented, including …

The complexity of host–pathogen interactions often leads to distinct clinical outcomes upon
infection with different pathogen strains. In this Review, we explore the interactions between …

Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a
critical lack of methods for prevention of infection or treatment of acute infection and chronic …

Chagas disease is a leading cause of heart disease affecting approximately 10 million
people in Latin America and elsewhere worldwide. The two major drugs available for the …

Despite many years of investigation and discussion, the cause of disease in chronic
Trypanosoma cruzi infection remains a hotly debated topic. The primary point of contention …

CD8+ T cells are crucial to the control of Trypanosoma cruzi infection and probably act via
multiple mechanisms, the most important being the production of interferon‐γ (IFN‐γ). In the …

Over 100 years have elapsed since the discovery of Chagas disease and there is still much
to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs …

In the past ten years, studies have shown the recognition of Trypanosoma cruzi‐associated
molecular patterns by members of the Toll‐like receptor (TLR) family and demonstrated the …

Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a prototypical
neglected tropical disease. Specific immunity promotes acute phase survival. Nevertheless …